Chapman Financial Group LLC Takes $1.23 Million Position in Johnson & Johnson (NYSE:JNJ)

Chapman Financial Group LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,480 shares of the company's stock, valued at approximately $1,226,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $33,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JNJ shares. Barclays cut their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Johnson & Johnson Stock Down 0.3 %

NYSE JNJ traded down $0.40 during mid-day trading on Tuesday, reaching $154.60. 8,634,326 shares of the company's stock traded hands, compared to its average volume of 7,890,008. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $371.97 billion, a price-to-earnings ratio of 23.25, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a fifty day simple moving average of $158.51 and a 200-day simple moving average of $154.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.